

Luis Enrique Morano Amado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2662873/publications.pdf>

Version: 2024-02-01

16
papers

165
citations

1306789

7
h-index

1125271

13
g-index

16
all docs

16
docs citations

16
times ranked

402
citing authors

#	ARTICLE	IF	CITATIONS
1	Ten steps to eliminating hepatitis C in hospitals. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 481-483.	8.2	8
2	Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. <i>Clinical Infectious Diseases</i> , 2021, 73, e2109-e2116.	2.9	10
3	A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. <i>Diagnostics</i> , 2021, 11, 1501.	1.3	2
4	Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110247.	0.6	3
5	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 28-32.	0.3	15
6	Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 127-131.	0.3	7
7	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfecting with human immunodeficiency virus-1 in Spain. <i>PLoS ONE</i> , 2019, 14, e0225061.	1.1	4
8	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice “Vie-KinD study. <i>PLoS ONE</i> , 2019, 14, e0221567.	1.1	7
9	Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. <i>PLoS ONE</i> , 2019, 14, e0217052.	1.1	5
10	Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz070.	0.4	20
11	HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. <i>Aids</i> , 2019, 33, 1167-1174.	1.0	15
12	Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfecting patients with genotype 1 in real-life practice. <i>HIV Clinical Trials</i> , 2018, 19, 23-30.	2.0	3
13	Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2018, 41, 597-608.	0.2	15
14	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. <i>Scientific Reports</i> , 2018, 8, 14905.	1.6	4
15	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx258.	0.4	21
16	Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. <i>Journal of Clinical Virology</i> , 2017, 88, 58-61.	1.6	26